Sumitomo Pharma Co., Ltd. (DNPUF)
9.27
+0.86
(+10.29%)
USD |
OTCM |
Aug 25, 16:00
Sumitomo Pharma Net Income (Quarterly) : 106.66M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 106.66M |
| March 31, 2026 | -5.175M |
| December 31, 2025 | 57.23M |
| September 30, 2025 | 594.56M |
| June 30, 2025 | 77.51M |
| March 31, 2025 | 15.85M |
| December 31, 2024 | 350.75M |
| September 30, 2024 | -322.74M |
| June 30, 2024 | 102.27M |
| March 31, 2024 | -1.328B |
| December 31, 2023 | -337.82M |
| September 30, 2023 | -199.74M |
| June 30, 2023 | -282.56M |
| March 31, 2023 | -484.05M |
| December 31, 2022 | -122.93M |
| September 30, 2022 | -313.26M |
| June 30, 2022 | 216.36M |
| March 31, 2022 | 46.57M |
| December 31, 2021 | 45.69M |
| September 30, 2021 | 265.07M |
| June 30, 2021 | 7.377M |
| March 31, 2021 | -198.67M |
| December 31, 2020 | 263.85M |
| September 30, 2020 | 139.18M |
| June 30, 2020 | 144.77M |
| Date | Value |
|---|---|
| March 31, 2020 | -73.97M |
| December 31, 2019 | 125.55M |
| September 30, 2019 | 220.12M |
| June 30, 2019 | 60.98M |
| March 31, 2019 | 78.60M |
| December 31, 2018 | 107.30M |
| September 30, 2018 | 113.23M |
| June 30, 2018 | 139.68M |
| December 31, 2017 | -12.78M |
| September 30, 2017 | 184.54M |
| June 30, 2017 | 221.53M |
| March 31, 2017 | -5.107M |
| December 31, 2016 | 170.30M |
| September 30, 2016 | 24.97M |
| June 30, 2016 | 77.52M |
| March 31, 2016 | 11.74M |
| December 31, 2015 | 83.43M |
| September 30, 2015 | 59.53M |
| June 30, 2015 | 48.93M |
| March 31, 2015 | -29.76M |
| December 31, 2014 | 63.22M |
| September 30, 2014 | 57.73M |
| June 30, 2014 | 56.38M |
| March 31, 2014 | 8.778M |
| December 31, 2013 | 104.21M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 710.72M |
| Daiichi Sankyo Co., Ltd. | 430.72M |
| Eisai Co., Ltd. | 120.18M |
| Chugai Pharmaceutical Co., Ltd. | 730.02M |
| Santen Pharmaceutical Co., Ltd. | 45.18M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 812.63M |
| Total Expenses (Quarterly) | 705.96M |
| EPS Diluted (Quarterly) | 0.2448 |
| Enterprise Value | 4.675B |
| Gross Profit Margin (Quarterly) | 52.57% |
| Profit Margin (Quarterly) | 13.13% |
| Earnings Yield | 20.20% |
| Operating Earnings Yield | 8.30% |
| Normalized Earnings Yield | 20.20 |